These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36674549)

  • 1. Phosphatidylethanolamines Are Associated with Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Adults and Induce Liver Cell Metabolic Perturbations and Hepatic Stellate Cell Activation.
    Shama S; Jang H; Wang X; Zhang Y; Shahin NN; Motawi TK; Kim S; Gawrieh S; Liu W
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice.
    Yang A; Yan X; Fan X; Shi Y; Huang T; Li W; Chen W; Jia J; You H
    Hepatol Int; 2021 Oct; 15(5):1122-1135. PubMed ID: 34014450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine.
    Arendt BM; Ma DW; Simons B; Noureldin SA; Therapondos G; Guindi M; Sherman M; Allard JP
    Appl Physiol Nutr Metab; 2013 Mar; 38(3):334-40. PubMed ID: 23537027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease.
    Charlton M; Viker K; Krishnan A; Sanderson S; Veldt B; Kaalsbeek AJ; Kendrick M; Thompson G; Que F; Swain J; Sarr M
    Hepatology; 2009 Apr; 49(4):1375-84. PubMed ID: 19330863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects.
    Ma DW; Arendt BM; Hillyer LM; Fung SK; McGilvray I; Guindi M; Allard JP
    Nutr Diabetes; 2016 Jul; 6(7):e220. PubMed ID: 27428872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.
    Larsen FT; Hansen D; Terkelsen MK; Bendixen SM; Avolio F; Wernberg CW; Lauridsen MM; Grønkjaer LL; Jacobsen BG; Klinggaard EG; Mandrup S; Di Caterino T; Siersbæk MS; Indira Chandran V; Graversen JH; Krag A; Grøntved L; Ravnskjaer K
    JHEP Rep; 2023 Feb; 5(2):100615. PubMed ID: 36687468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading.
    Chu X; Jin Q; Chen H; Wood GC; Petrick A; Strodel W; Gabrielsen J; Benotti P; Mirshahi T; Carey DJ; Still CD; DiStefano JK; Gerhard GS
    J Transl Med; 2018 Apr; 16(1):108. PubMed ID: 29690903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Valenti L; Svegliati-Baroni G; Ruscica M; Pipitone RM; Dongiovanni P; Rychlicki C; Ferri N; Cammà C; Fracanzani AL; Pierantonelli I; Di Marco V; Meroni M; Giordano D; Grimaudo S; Maggioni M; Cabibi D; Fargion S; Craxì A
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2660-2669. PubMed ID: 28472477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8
    Breuer DA; Pacheco MC; Washington MK; Montgomery SA; Hasty AH; Kennedy AJ
    Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G211-G224. PubMed ID: 31709830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GDF11 induces mild hepatic fibrosis independent of metabolic health.
    Frohlich J; Kovacovicova K; Mazza T; Emma MR; Cabibi D; Foti M; Sobolewski C; Oben JA; Peyrou M; Villarroya F; Soresi M; Rezzani R; Cervello M; Bonomini F; Alisi A; Vinciguerra M
    Aging (Albany NY); 2020 Oct; 12(20):20024-20046. PubMed ID: 33126224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
    Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
    Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease.
    Kimura T; Singh S; Tanaka N; Umemura T
    Front Endocrinol (Lausanne); 2021; 12():773432. PubMed ID: 34938271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemokine ligand 20 (CCL20) expression increases with NAFLD stage and hepatic stellate cell activation and is regulated by miR-590-5p.
    Hanson A; Piras IS; Wilhelmsen D; Still CD; Chu X; Petrick A; Gerhard GS; DiStefano JK
    Cytokine; 2019 Nov; 123():154789. PubMed ID: 31352173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingomyelin synthase-related protein SMSr is a phosphatidylethanolamine phospholipase C that promotes nonalcoholic fatty liver disease.
    Chiang YP; Li Z; He M; Jones Q; Pan M; Han X; Jiang XC
    J Biol Chem; 2023 Sep; 299(9):105162. PubMed ID: 37586586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease.
    Arndt S; Wacker E; Dorn C; Koch A; Saugspier M; Thasler WE; Hartmann A; Bosserhoff AK; Hellerbrand C
    Gut; 2015 Jun; 64(6):973-81. PubMed ID: 25011936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.